FDA Drug Name Guidance Is “Premature” Without More Data, Cmte. Says

Development of an FDA guidance on how to screen proprietary drug names for potential medication errors would be premature without more outcomes data, the Drug Safety & Risk Management Advisory Committee agreed Dec. 4